Translational biomarkers play an important role in drug discovery, helping researchers understand disease mechanisms, evaluate therapeutic responses, and generate data that supports progression from preclinical studies to clinical development (1, 2). Within immunology and inflammation research, the complement system has emerged as an important source of biomarkers that can provide insight into immune activation and disease progression (3, 4).
Dysregulation of the complement system has been implicated in a wide range of conditions, including autoimmune and inflammatory diseases, kidney disorders, neurodegenerative diseases, cardiovascular disease, infection, and cancer, making complement biomarkers increasingly valuable in both translational research and drug development (1, 3, 4).
To support complement research, Hycult Biotech offers a broad portfolio of ELISA kits designed to measure complement proteins, activation products, and pathway activity across a range of research applications. These assays help researchers generate reliable data for biomarker discovery, mechanistic studies, and preclinical evaluation.
Assessing complement activation in research applications
Measuring complement activation products can provide a direct indication of complement pathway activity. Unlike native complement proteins, these biomarkers are generated during activation of the cascade and can therefore help researchers monitor biological responses, assess therapeutic effects, and study disease-associated inflammation (3, 4).
Key complement biomarkers in translational research
C3a: an early indicator of complement activation
C3a is generated during activation of the complement cascade and contributes to a range of inflammatory and immune responses (3, 5). As a result, it is frequently studied in areas including infectious disease, autoimmune disorders, cardiovascular research, and nephrology. Hycult Biotech's C3a ELISA is designed to detect the stable C3a-desArg form, enabling accurate measurement of complement activation.
C5a: an important mediator of inflammation
C5a is a biologically active complement fragment involved in immune cell recruitment and inflammatory signalling. It has been associated with a variety of inflammatory and immune-mediated conditions and is commonly used as a biomarker in both basic and translational research (5). Hycult Biotech's C5a ELISA provides specific quantification of this key complement activation product.
sC5b-9 (TCC): an established marker of terminal complement activation
Soluble C5b-9 (sC5b-9), also known as Terminal Complement Complex (TCC), represents the final stage of complement activation. Because it reflects activation of the complement cascade regardless of the initiating pathway, it is widely used to assess overall complement activity in both preclinical and clinical research (3, 6).
Applications of sC5b-9 analysis include:
- Evaluating complement activation in disease models
- Assessing the activity of complement-targeted therapies
- Monitoring pharmacodynamic responses
- Supporting translational biomarker studies
- Comparing complement activity across study stages
Supporting translational research
With assays available for human, rodent, porcine, and non-human primate studies, Hycult Biotech's complement ELISA portfolio supports researchers throughout the drug development process. By enabling consistent measurement of complement biomarkers across species, these tools can help strengthen the translational relevance of preclinical findings and support informed research decisions (1, 2).
As interest in complement-targeted therapeutics continues to grow, robust biomarker analysis remains an important component of successful research programmes. The complement ELISA portfolio from Hycult Biotech provides researchers with well-characterised tools for studying complement biology and generating data that can support translational research objectives.
Learn more and explore our drug discovery workflow.
References
1. Ricklin D, Mastellos DC, Reis ES, Lambris JD. The Renaissance of Complement Therapeutics. Nat Rev Nephrol. 2018;14(1):26-47.
2. Hycult Biotech. Complement Research in Drug Development.
3. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: A Key System for Immune Surveillance and Homeostasis. Nat Immunol. 2010;11(9):785-797.
4. Brandwijk RJMGE, Michels MAHM, van Rossum M, et al. Pitfalls in Complement Analysis: A Systematic Literature Review of Assessing Complement Activation. Front Immunol. 2022;13:1007102.
5. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Kohl J. The Role of the Anaphylatoxins in Health and Disease. Mol Immunol. 2009;46(14):2753-2766.
6. Profaizer T, Saadalla A, Nandakumar V. Validation for Soluble C5b-9 Detection and Comparative Analysis of Three Quantification Methods. J Immunol Methods. 2025;541:113882.